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Abstract
Background: Acute heart failure patients could benefit from heart rate reduction, as myocardial con-
sumption and oxidative stress are related to tachycardia. Ivabradine could have a clinical role attenuat-
ing catecholamine-induced tachycardia. The aim of this study was to evaluate hemodynamic effects of 
ivabradine in a swine model of acute heart failure. 
Methods: Myocardial infarction was induced by 45 min left anterior descending artery balloon occlu-
sion in 18 anesthetized pigs. An infusion of dobutamine and noradrenaline was maintained aiming to 
preserve adequate hemodynamic support, accompanied by fluid administration to obtain a pulmonary 
wedged pressure ≥ 18 mmHg. After reperfusion, rhythm and hemodynamic stabilization, the animals 
were randomized to 0.3 mg/kg ivabradine intravenously (n = 9) or placebo (n = 9). Hemodynamic 
parameters were observed over a 60 min period. 
Results: Ivabradine was associated with a significant reduction in heart rate (88.4 ± 12.0 bpm vs. 
122.7 ± 17.3 bpm after 15 min of ivabradine/placebo infusion, p < 0.01) and an increase in stroke vol-
ume (68.8 ± 13.7 mL vs. 52.4 ± 11.5 mL after 15 min, p = 0.01). There were no significant differences 
in systemic or pulmonary arterial pressure, or significant changes in pulmonary capillary pressure. 
However, after 15 min, cardiac output was significantly reduced with ivabradine (–5.2% vs. +15.0% 
variation in ivabradine/placebo group, p = 0.03), and central venous pressure increased (+4.2% vs. 
–19.7% variation, p < 0.01). 
Conclusions: Ivabradine reduces heart rate and increases stroke volume without modifying systemic 
or left filling pressures in a swine model of acute heart failure. However, an excessive heart rate reduc-
tion could lead to a decrease in cardiac output and an increase in right filling pressures. Future studies 
with specific heart rate targets are needed. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
Acute heart failure (AHF) continues to be as-
sociated with poor prognosis and high in-hospital 
mortality [1]. Inotropic drugs are the cornerstone 
in management of hypotensive (cold) AHF pa-
tients, promoting a dose-dependent increase in 
cardiac output (CO) and reduction of left ventricle 
(LV) filling pressures. The downside to these 
effects is an increase in heart rate (HR) with its 
corresponding increase in myocardial oxygen con-
sumption [2–5]. European Society of Cardiology 
guidelines recommend a limited use of inotropic 
agents in the management of AHF [1], recogniz-
ing sinus tachycardia as possibly deleterious, as it 
may compromise ventricular filling efficiency by 
shortening diastolic duration [6]. Accordingly, re-
duction of HR could be an important energy-saving 
maneuver in AHF. 
Ivabradine is a specific blocker of the If “funny” 
currently supported by hyperpolarization-activat-
ed cyclic nucleotide-gated channels, regulating 
sinoatrial node activity. Its pharmacological effects 
are deemed to be almost exclusively on the sinus 
node reducing HR without affecting myocardial 
contractility or vascular tone. Ivabradine has been 
shown to reduce re-hospitalization and mortality 
rates in patients with chronic HF and ≤ 35% left 
ventricular ejection fraction (LVEF) [1, 7, 8], but 
it has not been adequately tested in AHF. It has 
been postulated that ivabradine could have a role 
attenuating catecholamine-induced tachycardia [5, 
6]. Few case series and reports suggest its safety 
and potential benefit, improving surrogate end-
points in AHF and cardiogenic shock (CS) [9–12]. 
However, the effects of rapid reduction of HR on 
CO or heart filling pressures in this context are not 
clearly understood and a comprehensive analysis of 
hemodynamic of ivabradine effects in this setting 
is warranted.
The main objective of this study was to evalu-
ate the impact of ivabradine on hemodynamic 
parameters in a swine model of AHF.
Methods
Ethical approval
All procedures were performed in the Ex-
perimental Surgery Department of the Hospital 
Universitario La Paz (Madrid, Spain).  Protocol 
was followed and approved by the Animal Welfare 
Ethics Committee. The investigation conforms to 
Guide for the Care and Use of laboratory Animals, 
published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1985) and 
complied with the EU Directive on experimental 
animals (63/2010 EU) and related Spanish legisla-
tion (RD 53/2013). PROEX 365-15.
Surgery and instrumentation
Eighteen Large White female pigs (37.6 ± 
5.1 kg) were used in the study. The animals were 
initially treated with intramuscular ketamine (10 
mg/kg, Pfizer) and midazolam (0.5 mg/kg, Braun). 
Anesthesia was induced by inhaled isoflurane (Ab-
bvie Spain SLU) and maintained with continuous 
infusion of propofol (2 mL/kg/h, Fresenius Kabi), 
fentanyl (50 µg/kg/h, Kern Pharma) and diazepam 
(10 µg/kg/h, Roche). Animals were intubated and 
ventilated with 60% oxygen saturation. A central 
venous catheter (Swan-Ganz oximetry thermodi-
lution catheter, Edwards Lifesciences) was placed 
through the right internal jugular vein to the pul-
monary artery for measurement of central venous 
pressure (CVP), CO, pulmonary capillary wedge 
pressure (PCWP), pulmonary artery pressure 
(PAP) and mixed venous oxygen saturation (SvO2). 
Systemic arterial pressure (SAP) was measured in 
the ascending aorta through the guiding catheter 
used to catheterize the left coronary artery tree. 
The animals received 5000 IU of heparin and 
amiodarone (53 μg/kg/min, Sanofi Aventis) to avoid 
blood clotting of catheters and malignant cardiac 
arrhythmias, respectively. Animals were stabilized 
for 15 min before baseline measurements (T0).
Experimental protocol
The experimental protocol is outlined in Figure 1. 
After baseline measurements, including echo-
cardiogram and hemodynamic assessment, acute 
anterior myocardial infarction was induced by mid-
left anterior descending artery (LAD) occlusion for 
45 min using a JL 3 6 F catheter and 3.0 or 3.5 mm 
conventional angioplasty balloons. Hemodynamic 
measurements were continuously monitored and 
recorded at 15, 30 and 45 min during ischemia 
(T15, T30, T45). Noradrenaline (0.4–0.8 µg/kg/min, 
Braun), dobutamine (2.9–6.2 µg/kg/min, Hospira 
Productos farmacéuticos y Hospitalarios SL) and 
physiological saline (1000–2000cc, Grifols) were 
administered after the first 15 min of occlusion to 
maintain adequate systemic perfusion and titrated 
to obtain a HR ≥ 90 bpm and PCWP > 18 mmHg. 
After 45 min of coronary occlusion, the angioplasty 
balloon was deflated and at least 15 min of electrical 
and hemodynamic stabilization time was allowed 
before infusion of study drug or placebo. Hemo-
dynamic measurements were recorded (T60) and 
www.cardiologyjournal.org 3
Marina Pascual Izco et al., Ivabradine in acute heart failure
animals were then randomized to a control group 
(n = 9) or to receive ivabradine (n = 9). Accord-
ing to Servier laboratories instructions, ivabradine 
powder was diluted in distilled water in a propor-
tion of at least 12 mg/mL and administered intra-
venously in slow bolus at a dose of 0.3 mg/kg. This 
dose was chosen based on evidence available in the 
literature on the effect of intravenously ivabradine 
in porcine and human models, with doses between 
0.1 mg/kg and 0.6 mg/kg [13–16].  The control group 
received an equivalent volume of physiological sa-
line. Hemodynamic measurements were repeated 
15-30-45 and 60 min after ivabradine/placebo ad-
ministration (T75, T90, T105, T120).
Statistical analysis
All data were analyzed with a statistical soft-
ware package (Stata 13.0 statistical software (Stata 
Corporation, College Station, TX)). All values are 
given as mean ± standard deviation. A two-sided 
p < 0.05 was considered significant. Saphiro-Wilk 
test was used to assess variable distribution.
Statistical analysis was performed in two 
phases. Firstly, individual variables were assessed 
before and after coronary occlusion in the same 
animal. The Student t-test for paired data was used 
to analyze variables of normal distribution, and 
Wilcoxon test was used in non-normal distribu-
tion variables. Secondly, hemodynamic effects of 
ivabradine were compared with placebo. The Stu-
dent t-test for unpaired data was used in variables 
of normal distribution, and Mann-Whitney U test 
was used in variables of non-normal distribution.
Results
Effects of coronary occlusion  
on hemodynamic parameters
The accumulated ischemia time was 45.3 ± 1.2 
min. Ventricular fibrillation necessitating external 
defibrillation occurred on average 1.9 times per 
animal. The induction of ischemia led to a signifi-
cant decline in SAP and CO in the first 15 min after 
LAD occlusion (Table 1). Following dobutamine and 
noradrenaline administration, HR, PCWP, PAP and 
CVP increased progressively (Table 1). 
Effects of ivabradine on  
hemodynamic parameters
Hemodynamic variables for ivabradine-treated 
animals and controls are summarized in Tables 2 
and 3 and Figure 2. Table 2 expresses absolute 
values. Study groups had comparable HR and sys-
temic or pulmonary perfusion and filling pressures 
at baseline. Ivabradine administration produced 
a significant reduction in HR (at 15 min: –21.9% 
reduction vs. 2.6% increase; p < 0.01). Parallel to 
this rapid reduction in HR, we observed a signifi-
Figure 1. Outline of the experimental protocol. After baseline assessment of hemodynamics parameters, animals 
underwent left anterior descending artery (LAD) occlusion. Hemodynamic measurements were recorded at 15, 30 
and 45 min of ischemia. After LAD reperfusion, pigs were allowed to stabilize for another 15 min before recording 
the pre-randomization measurements. Animals were then randomized to receive ivabradine (0.3 mg/kg) of either 
placebo. Hemodynamic measurements were repeated 15-30-45 and 60 min after ivabradine/placebo administration; 
HR — heart rate; PCWP — pulmonary capillary wedge pressure.
9 animals
Ivabradine (0.3 mg/kg)
9 animals
Placebo
T0 
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Post-
Ischemia
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T30
Post-
Ischemia
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T45
Post-
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Pre-
Randomization
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T75
Post-
Randomization
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T90
Post-
Randomization
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Randomization
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cant CO reduction in response to ivabradine (at 15 
min: –5.2% reduction vs. +15.0% increase; p = 
0.03), that remained stable during the following 
45 min (Table 3, Fig. 2). Despite reduction of HR 
and CO no significant changes in perfusion or left 
filling pressures were observed (SAP, PCWP and 
PAP in Tables 2 and 3 and Fig. 2). After ivabradine 
bolus there was a corresponding increase in stroke 
volume (SV), compared to placebo values (+21.5% 
vs. +13.6% increase, ivabradine and placebo re-
spectively; p = 0.34), which tended to stabilize 
during the 60 min observation period (Table 2, Fig. 
2). Finally, a significant reduction in right filling 
pressure was observed (CVP) in the control group, 
and not observed in the ivabradine-assigned group 
(+4.2% increase vs. –19.7% reduction after 15 min 
ivabradine/placebo administration, p < 0.01). 
Discussion
This is an open-label randomized study evalu-
ating the hemodynamic effects of ivabradine in an 
experimental model of AHF based on an acute 
myocardial infarction-reperfusion injury. LAD oc-
clusion led to a significant decline in mean arterial 
pressure (MAP) and CO similar to other studies 
with the same characteristics [17]. The rapid 
reduction of HR induced by an intravenous bolus 
of ivabradine produced a reduction in CO with a 
corresponding increase in SV, with no changes in 
systemic or pulmonary arterial pressures. There 
were no acute changes in left filling pressures, 
while there was a spontaneous decrease in right 
filling pressures in control animals, not observed in 
the ivabradine group. An observed reduction in CO 
was not progressive and both perfusion and heart 
filling pressures tended to remain stable after the 
first hour of drug administration. 
Tachycardia is a common and physiological 
response to vasodilation or reduction in effective 
perfusion pressures but can result in higher myo-
cardial oxygen consumption and lower coronary 
filling time. Higher HR has been shown to predict 
a worse prognosis in both AHF and chronic de-
compensated HF [18, 19]. After demonstration 
of reduction of HR with ivabradine in chronic HF 
[7, 8], several studies have suggested a possible 
role of rapid lowering HR during hospitalization in 
AHF patients or CS [9–12, 20–23]. However, few 
data are available on the hemodynamics of rapidly 
reducing HR in AHF. Gallet et al. [9] evaluated the 
effects of combining dobutamine and ivabradine (5 
mg bid) in 9 patients with refractory CS. Ivabradine 
not only reduced HR, but also improved SAP, CO 
and N-terminal pro-B-type natriuretic peptide (NT-
proBNP) values. Cavusoglu et al. [22] randomized 
58 patients with AHF requiring inotropic support 
to receive ivabradine (n = 29) or placebo (n = 29) 
in addition to dobutamine. In the control group, 
mean HR gradually and significantly increased 
Table 1. Parameters before left anterior descendent artery (LAD) occlusion; parameters 15, 30 and 45 min 
after LAD occlusion and 15 min after reperfusion.
Effects of coronary occlusion on hemodynamic parameters
Hemodynamic  
parameters  
(n = 18)
LAD occlusion LAD reperfusion
+ DB/NA
Basal LAD  
15 min
LAD 30 min 
+ DB/NA
LAD 45 min 
+ DB/NA
SAP [mmHg] 95.1 ± 14.4 87.2 ± 14.2* 95.3 ± 24.3 101.2 ± 12.5 105.2 ± 12.3*
MAP [mmHg] 73.6 ± 10.2 68.1 ± 12.5 74.7 ± 20.4 78.3 ± 12.5 71.2 ± 11.4
CO [l/min] 5.2 ± 1.1 4.6 ± 1.3* 5.0 ± 1.2 5.6 ± 1.1 6.10± 1.4*
SV [mL] 59.9 ± 12.0 51.6 ± 15.5** 50.9 ± 14.0** 56.3 ± 12.8 51.4 ± 11.6**
HR [bpm] 88.1 ± 17.5 90.3 ± 13.6 98.8 ± 13.0* 99.9 ± 12.5* 116.4 ± 16.5**
PCWP [mmHg] 16.0 ± 3.0 18.8 ± 3.0** 21.1 ± 3.9** 20.9 ± 3.0** 23.4 ± 3.8**
MPAP [mmHg] 23.7 ± 5.2 24.4 ± 5.7 25.7 ± 6.6 27.9 ± 6.0** 31.4 ± 6.5**
CVP [mmHg] 9.9 ± 2.9 11.4 ± 2.8* 12.6 ± 3.1** 13.5 ± 3.0** 13.7 ± 3.2**
SVO2 [%] 69.4 ± 12.6 65.0 ± 7.0 72.3 ± 8.9 77.7 ± 6.8* 76.9 ± 7.4*
Values are expressed as mean ± standard deviation. LAD occlusion led to a significant decline in MAP, CO and SV in the first 15 min after LAD 
occlusion. Dobutamine and noradrenaline, along with fluids, were administered after 15 min of occlusion to preserve adequate hemodynam-
ics during induction of myocardial infarction. *p < 0.05; **p < 0.01. N = 18 (all animals, both groups); DB — dobutamine; NA — noradrena-
line; SAP — systolic arterial pressure; MAP — mean arterial pressure; CO — cardiac output; SV — stroke volume; HR — heart rate; PCWP 
— pulmonary capillary wedge pressure; MPAP — mean pulmonary artery pressure; CVP — central venous pressure; SVO2 — mixed venous 
oxygen saturation
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Figure 2. Ivabradine and placebo hemodynamic parameters variations; *p < 0.05 for effect of ivabradine vs. placebo 
on hemodynamic parameters; **p < 0.01 for effect of ivabradine vs. placebo on hemodynamic parameters; N = 9 
— ivabradine group; N = 9 — placebo group.
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at each step of dobutamine infusion, whereas no 
significant increase in HR was observed in the iv-
abradine group. However, important hemodynamic 
parameters, such as PCWP, SAP or CO were not 
recorded in these studies. In a study by Barillá et al 
[23], a total of 58 patients with CS as a complication 
of acute elevation myocardial infarction and HR 
> 75 bpm were randomized to standard treatment 
or to standard treatment plus ivabradine. HR was 
significantly reduced in ivabradine group, without 
modifying SAP. In-hospital mortality was doubled 
in the standard group in comparison with the stan-
dard plus ivabradine group, but the difference was 
not statistically significant. Nevertheless, invasive 
hemodynamic parameters such as CO or SV were 
not measured in this study. The MODIFY trial  [24] 
enrolled 70 patients with multiple organ dysfunc-
tion syndrome (MODS) and HR > 90 bpm. Patients 
were randomized to receive standard treatment 
plus ivabradine or placebo. The HR reduction from 
enteral administration of ivabradine was not associ-
ated with an improvement in hemodynamic values 
or disease severity among critically ill patients 
with MODS. However, this study included patients 
with MODS but not necessarily with CS or AHF. 
In fact, coronary etiology was identified in only 
17 patients; but important information as LVEF 
or filling pressure values was not registered. On 
the other hand, patients enrolled in the MODIFY 
trial received mainly vasopressor drugs instead of 
inotropic drugs. The present study focuses on the 
role of ivabradine in tachycardia induced by ino-
tropic drugs (mainly dobutamine) in patients with 
AHF and depressed LVEF. Target HR may not be 
the same for patients with preserved or reduced 
cardiac inotropism, but the effect of ivabradine on 
hemodynamic parameters in this kind of patient 
have not been studied in any human clinical trial 
yet.
In one experimental swine model, Bakkehaug 
et al. [25] presented an ischemia–reperfusion 
protocol in 12 pigs after intermittent ligation of 
the left coronary arteries. Dobutamine infusion in 
post-ischemic heart increased CO by increasing 
significantly HR from 102 to 131 bpm (p < 0.05). 
The analysis demonstrated that adding ivabradine 
to dobutamine reported a reduction of HR to base-
line values (100 bpm) without any effect on CO or 
MAP, with a significant increase in SV. However, 
in this study the hemodynamic effects of ivabra-
dine were not determined in different groups, but 
the same animal was compared with itself before 
and after ivabradine administration. Therefore, it 
is impossible to overrule a “self-recovery” effect 
after releasing left coronary occlusion. 
In the present study, ivabradine significantly 
reduced HR with no effect on SAP or PCWP. In 
contrast to previous observations and despite 
a rapid increase in SV, a decrease in CO values was 
observed when compared to control animals. How-
ever, the following limitations should be taken into 
consideration. First of all, the observation period 
(60 min) could be too short to detect a possible 
“catch-up” effect on CO values or stabilization of 
right or left filling pressures. Secondly, the experi-
mental model in this study was unable to produce 
a sustained reduction in CO as in pump failure due 
to acute myocardial infarction and actually several 
animals showed a high-CO state induced by cat-
echolamine infusion. And finally, this is a modest 
sample. Thus, caution is suggested in extrapolat-
ing this observed effect on CO to “clinical CS”. 
Despite these important limitations, it is believed 
herein that rapid and excessive HR reduction as 
produced by this model might be inappropriate in a 
clinical scenario. Accordingly, it may be postulated 
that there could be a specific ideal HR target, ad-
justed to individual clinical scenarios, and that an 
excessive attenuation of tachycardia response to 
endogenous or therapeutic catecholamines could 
be deleterious, leading to increased filling pres-
sures and reduction of CO. 
Another unique finding of in the present 
results was higher CVP values in the ivabradine 
group compared with the placebo group, with no 
clear effects on PCWP. It is possible that preserv-
ing an adequate HR in the ischemia-reperfusion 
model could be more important to right-ventricle 
filling pressures that left-ventricle mechanics. 
These data should be confirmed in robust future 
studies with longer observation times and, ideally, 
clinical endpoints. 
This study has some limitations that should 
be considered. First, anesthetic drugs could exert 
a vasodilatory effect not present in clinical mod-
els of AHF, although the same anesthetics were 
used in the ivabradine and control group. Second, 
dobutamine and noradrenaline were administered 
to induce tachycardia and maintain adequate sys-
temic perfusion. Cathecolamine infusion produced 
a high-output state in some experimental animals 
could have had an important interaction with the 
hemodynamic effects of the study drug. Finally, 
operators were blinded to the product administered 
after the occlusion phase (ivabradine or saline infu-
sion). However, masking the chronotropic effects 
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of ivabradine was not possible, reducing the impact 
of a blind design.
Conclusions
In conclusion, in a swine model of myocardial 
ischemia-reperfusion injury and AHF, ivabradine 
effectively attenuates catecholamine-induced 
tachycardia and acutely increases SV and diastolic 
filling time without affecting systemic or left-heart 
filling pressures. However, in this experimental 
model, an excessive HR reduction produced lower 
CO values. Future studies with more specific HR 
targets are needed to evaluate  possible benefits 
of ivabradine in this context.
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